Sexual Dysfunction Induced by Antidepressants-A Pharmacovigilance Study Using Data from VigiBase^TM

Area of Science:

• Pharmacovigilance
• Neuroscience
• Clinical Pharmacology

Background:

• Sexual dysfunction is a prevalent and often distressing side effect of antidepressant medications.
• This significantly impacts patient quality of life and adherence to treatment regimens.
• Understanding the specific drug-associated risks is essential for clinical practice.

Purpose of the Study:

• To investigate the association between various antidepressants and sexual dysfunction.
• To explore the pharmacodynamic underpinnings of antidepressant-induced sexual side effects.
• To provide data supporting informed clinical decision-making regarding antidepressant selection.

Main Methods:

• Analysis of individual case safety reports from VigiBase™.
• Calculation of reporting odds ratios (RORs) for sexual dysfunction adverse events.
• Correlation analysis between RORs and antidepressant binding affinities to neurotransmitter targets.

Main Results:

• High disproportional reporting of sexual dysfunction identified for selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
• Lower reported associations for agomelatine, bupropion, and mirtazapine.
• Significant positive correlation found between serotonin transporter binding affinity and sexual desire side effects (r = 0.67, p = 0.001).

Conclusions:

• Clinicians must proactively consider and manage sexual side effects when prescribing antidepressants.
• Pharmacodynamic properties, particularly serotonin transporter interaction, are implicated in sexual dysfunction.
• Improved patient outcomes depend on monitoring and addressing these adverse effects.